Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
TEVA's Cash-to-Debt is ranked lower than
97% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. TEVA: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.21 Max: 1.03
Current: 0.03
0.03
1.03
Equity-to-Asset 0.25
TEVA's Equity-to-Asset is ranked lower than
90% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TEVA: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.48 Max: 0.59
Current: 0.25
0.25
0.59
Debt-to-Equity 1.87
TEVA's Debt-to-Equity is ranked lower than
93% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. TEVA: 1.87 )
Ranked among companies with meaningful Debt-to-Equity only.
TEVA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29  Med: 0.64 Max: 1.87
Current: 1.87
0.29
1.87
Debt-to-EBITDA -2.11
TEVA's Debt-to-EBITDA is ranked lower than
99.99% of the 511 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. TEVA: -2.11 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TEVA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.11  Med: 2.97 Max: 12.37
Current: -2.11
-2.11
12.37
Piotroski F-Score: 4
Altman Z-Score: -0.38
Beneish M-Score: -3.88
WACC vs ROIC
3.48%
-22.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -78.11
TEVA's Operating Margin % is ranked lower than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.71 vs. TEVA: -78.11 )
Ranked among companies with meaningful Operating Margin % only.
TEVA' s Operating Margin % Range Over the Past 10 Years
Min: -78.11  Med: 13.92 Max: 24.01
Current: -78.11
-78.11
24.01
Net Margin % -72.66
TEVA's Net Margin % is ranked lower than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. TEVA: -72.66 )
Ranked among companies with meaningful Net Margin % only.
TEVA' s Net Margin % Range Over the Past 10 Years
Min: -72.66  Med: 8.87 Max: 20.66
Current: -72.66
-72.66
20.66
ROE % -58.44
TEVA's ROE % is ranked lower than
86% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. TEVA: -58.44 )
Ranked among companies with meaningful ROE % only.
TEVA' s ROE % Range Over the Past 10 Years
Min: -65.19  Med: 7.33 Max: 16.18
Current: -58.44
-65.19
16.18
ROA % -19.03
TEVA's ROA % is ranked lower than
79% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. TEVA: -19.03 )
Ranked among companies with meaningful ROA % only.
TEVA' s ROA % Range Over the Past 10 Years
Min: -19.88  Med: 3.53 Max: 9.34
Current: -19.03
-19.88
9.34
ROC (Joel Greenblatt) % -206.14
TEVA's ROC (Joel Greenblatt) % is ranked lower than
85% of the 850 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.46 vs. TEVA: -206.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -206.93  Med: 27 Max: 49.49
Current: -206.14
-206.93
49.49
3-Year Revenue Growth Rate -2.30
TEVA's 3-Year Revenue Growth Rate is ranked lower than
75% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 14.8 Max: 23.8
Current: -2.3
-2.3
23.8
GuruFocus has detected 3 Warning Signs with Teva Pharmaceutical Industries Ltd TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEVA's 30-Y Financials

Financials (Next Earnings Date: 2018-05-11)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

TEVA Guru Trades in Q1 2017

Francis Chou 215,000 sh (New)
Caxton Associates 12,200 sh (New)
Jim Simons 4,817,763 sh (+122.44%)
Vanguard Health Care Fund 11,717,600 sh (+31.33%)
Manning & Napier Advisors, Inc 96,678 sh (+15.05%)
NWQ Managers 926,179 sh (+7.84%)
Michael Price 720,000 sh (+3.37%)
Julian Robertson 557,600 sh (+0.50%)
George Soros 600,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Steven Cohen 50,000 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Jeremy Grantham Sold Out
Signature Select Canadian Fund Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
David Dreman 15,646 sh (-6.60%)
Barrow, Hanley, Mewhinney & Strauss 29,753,982 sh (-8.32%)
John Paulson 10,997,300 sh (-30.95%)
Ronald Muhlenkamp 106,645 sh (-55.54%)
David Tepper 2,175,000 sh (-56.96%)
Richard Snow 73,227 sh (-61.80%)
» More
Q2 2017

TEVA Guru Trades in Q2 2017

Bernard Horn 199,100 sh (+203.51%)
David Dreman 44,438 sh (+184.02%)
Francis Chou 505,000 sh (+134.88%)
Vanguard Health Care Fund 15,965,000 sh (+36.25%)
Julian Robertson 694,600 sh (+24.57%)
Ray Dalio 27,700 sh (+12.15%)
Caxton Associates 13,000 sh (+6.56%)
NWQ Managers 967,279 sh (+4.44%)
Barrow, Hanley, Mewhinney & Strauss 29,963,830 sh (+0.71%)
First Eagle Investment 200 sh (unchged)
Michael Price 720,000 sh (unchged)
George Soros 600,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Jim Simons Sold Out
David Tepper Sold Out
Ronald Muhlenkamp 106,505 sh (-0.13%)
Richard Snow 63,752 sh (-12.94%)
John Paulson 6,744,000 sh (-38.68%)
» More
Q3 2017

TEVA Guru Trades in Q3 2017

David Abrams 21,623,886 sh (New)
Steven Cohen 125,000 sh (New)
Vanguard Health Care Fund 27,180,276 sh (+70.25%)
Caxton Associates 13,300 sh (+2.31%)
Bernard Horn 199,100 sh (unchged)
First Eagle Investment 200 sh (unchged)
Ronald Muhlenkamp 13,000 sh (unchged)
Ray Dalio 27,700 sh (unchged)
George Soros 1,190,000 sh (unchged)
Francis Chou 505,000 sh (unchged)
Richard Snow Sold Out
Julian Robertson Sold Out
NWQ Managers 953,454 sh (-1.43%)
David Dreman 42,048 sh (-5.38%)
John Paulson 2,450,000 sh (-63.67%)
Barrow, Hanley, Mewhinney & Strauss 4,716,868 sh (-84.26%)
Michael Price 54,875 sh (-92.38%)
Ronald Muhlenkamp 700 sh (-99.34%)
» More
Q4 2017

TEVA Guru Trades in Q4 2017

Francisco García Paramés 696,509 sh (New)
Pioneer Investments 59,042 sh (New)
Jana Partners 3,582,713 sh (New)
Warren Buffett 18,875,721 sh (New)
Steven Cohen 327,650 sh (+162.12%)
Michael Price 104,875 sh (+91.12%)
NWQ Managers 1,204,186 sh (+26.30%)
Vanguard Health Care Fund 31,351,001 sh (+15.34%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 27,700 sh (unchged)
Ronald Muhlenkamp 700 sh (unchged)
Ronald Muhlenkamp 13,000 sh (unchged)
George Soros 1,190,000 sh (unchged)
Caxton Associates Sold Out
John Paulson Sold Out
David Abrams 19,743,123 sh (-8.70%)
Barrow, Hanley, Mewhinney & Strauss 2,878,493 sh (-38.97%)
Francis Chou 15,000 sh (-97.03%)
David Dreman 161 sh (-99.62%)
» More
» Details

Insider Trades

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF.PFD371.0917.997 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NSE:SUNPHARMA, TSE:4507, NAS:MYL, SHSE:600196, SZSE:000538, TSE:4523, SHSE:600518, NYSE:PRGO, TSE:4508, XPAR:IPN, OCSE:LUN, XSWX:VIFN, SHSE:600276, HKSE:03320, JSE:APN, SZSE:000963, SZSE:300122, SZSE:002001, SHSE:600085, BSP:HYPE3 » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Bernard Horn Comments on Teva Pharmaceutical - Oct 18, 2017

Teva Pharmaceutical (NYSE:TEVA), the Israeli drug company, dropped materially during the quarter. The company faced a perfect storm of industry pressures and self-inflicted missteps. Pricing pressure in the U.S. generics market was worse than normal. The resultant lower cash flow, and a high debt load from the Allergan acquisition, forced the company to cut its dividend and warn that debt covenants may be violated. Management planned asset sales to help alleviate cash requirements. Generic drug competition also impacted Allergan, as the stock declined nearly 15% on concerns of a 2018 generic alternative to Allergan’s flagship Alzheimer’s drug, Namenda. However, Allergan’s current drug portfolio remains resilient, led by advances in Botox and the introduction of Namzaric. Company management also signaled its intention to add new medicines and expand via acquisitions.

From Bernard Horn (Trades, Portfolio)'s third quarter 2017 shareholder commentary.

Check out Bernard Horn latest stock trades

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Should You Follow Buffett Into Teva Pharmaceutical? The company does not fit Warren Buffett's typical mold
Buying companies that have fallen out of favor with the rest of market has always been a skill of Warren Buffett (Trades, Portfolio) and his team at Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B). Read more...
Francis Chou Nearly Dumps Entire Stake in Valeant, Teva and Overstock in 4th Quarter Guru announces top three sells in latest portfolio update
Francis Chou (Trades, Portfolio), portfolio manager of Chou America Mutual Funds, disclosed Wednesday he nearly eliminated his stakes in three companies during fourth-quarter 2017: Valeant Pharmaceuticals International Inc. (NYSE:VRX), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Overstock.com Inc. (NASDAQ:OSTK). Read more...
Three Stocks Are Advancing Stocks move on results and fund acquisition
In Thursday trading, shares of Cisco Systems, Inc. (NASDAQ:CSCO) advanced by nearly 4% on the heels of the company reporting its financial results for the second quarter. Read more...
Warren Buffett’s Berkshire Buys Teva, Apple and Slashes IBM Legendary investor reports 4th-quarter portfolio
Warren Buffett (Trades, Portfolio)’s portfolio reveal Thursday showed that investment managers at his company bought shares of Teva Pharmaceuticals Industries (NYSE:TEVA), Monsanto Co. (NYSE:MON) and Apple (NASDAQ:AAPL) in the fourth quarter. The new filing also showed that Buffett nearly ended his stake in IBM Corp. (NYSE:IBM). Read more...
Francisco Garcia Parames Buys 19 Stocks in 4th Quarter Warren Buffett of Spain discloses portfolio
Often dubbed the “Warren Buffett (Trades, Portfolio) of Spain” for his value investing style, Spain’s Francisco Garcia Parames announced Friday that he bought 19 new stocks, giving his portfolio 30% turnover from the previous quarter. Read more...
Teva Is Playing Debt Roulette and It May Just Work Teva Pharmaceuticals is raising another $5 billion in debt. Depending on how it's done and what rates will be paid, it could make or break the company
Big developments are coming out of Teva Pharmaceuticals (NYSE:TEVA) this week. Some could either be the generic giant’s saving grace while others could sink the company. Read more...
David Abrams: A Seth Klarman Disciple Makes It on His Own Does he still outperform 97% of all hedge fund managers?
3 Stocks Move on Thursday Nordson, Teva Pharmaceutical rise, Valeant falls
Shares of Nordson Corp. (NASDAQ:NDSN) jumped more than 15% on the back of the company posting its financial results for the fourth quarter of 2017. The company reported revenue grew 12.7% to $573.94 million. EPS came in at $1.38. The company beat earnings estimates by five cents and revenue expectations by $28.79 million. Read more...
3 Stocks Moving Monday Rand Logistics, Square fall, Teva rises
Shares of Rand Logistics Inc. (RLOG) traded lower on Monday, continuing Friday's losses, following the announcement it will be acquired by American Industrial Partners. Under the terms of the deal, the latter will convert all of Rand Logistics' second lien debt into 100% of the new common equity of a reorganized company. As a result, the company will eliminate $90 million in outstanding debt and also reduce annual interest expenses. Read more...
US Stock Markets Rise to All-Time High on Black Friday Marathon Patent skyrockets after quarterly results
Wall Street is in green territory with the main indexes edging higher ahead of Black Friday. Investors should watch shares of retailers, such as Target (NYSE:TGT), Amazon (NASDAQ:AMZN) and Wal-Mart Stores (NYSE:WMT) in an abbreviated trading session for today. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 8.46
TEVA's Forward PE Ratio is ranked higher than
89% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. TEVA: 8.46 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.50
TEVA's PB Ratio is ranked higher than
87% of the 825 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. TEVA: 1.50 )
Ranked among companies with meaningful PB Ratio only.
TEVA' s PB Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.95 Max: 2.91
Current: 1.5
0.46
2.91
PS Ratio 0.89
TEVA's PS Ratio is ranked higher than
86% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TEVA: 0.89 )
Ranked among companies with meaningful PS Ratio only.
TEVA' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 2.49 Max: 4.33
Current: 0.89
0.5
4.33
Price-to-Free-Cash-Flow 7.71
TEVA's Price-to-Free-Cash-Flow is ranked higher than
89% of the 217 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.63 vs. TEVA: 7.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.12  Med: 13.01 Max: 32.03
Current: 7.71
4.12
32.03
Price-to-Operating-Cash-Flow 5.82
TEVA's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.74 vs. TEVA: 5.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.09  Med: 10.03 Max: 22.47
Current: 5.82
3.09
22.47
EV-to-EBIT -3.24
TEVA's EV-to-EBIT is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.21 vs. TEVA: -3.24 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.7  Med: 18.6 Max: 192.9
Current: -3.24
-14.7
192.9
EV-to-EBITDA -3.69
TEVA's EV-to-EBITDA is ranked lower than
99.99% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. TEVA: -3.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.3  Med: 13.7 Max: 39.1
Current: -3.69
-20.3
39.1
EV-to-Revenue 2.52
TEVA's EV-to-Revenue is ranked higher than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TEVA: 2.52 )
Ranked among companies with meaningful EV-to-Revenue only.
TEVA' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.1 Max: 4.6
Current: 2.52
2.1
4.6
Shiller PE Ratio 48.05
TEVA's Shiller PE Ratio is ranked lower than
63% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.75 vs. TEVA: 48.05 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 6.95  Med: 25.8 Max: 58.08
Current: 48.05
6.95
58.08
Current Ratio 0.86
TEVA's Current Ratio is ranked lower than
92% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. TEVA: 0.86 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.58 Max: 2.95
Current: 0.86
0.86
2.95
Quick Ratio 0.58
TEVA's Quick Ratio is ranked lower than
91% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. TEVA: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.99 Max: 2.18
Current: 0.58
0.58
2.18
Days Inventory 158.31
TEVA's Days Inventory is ranked lower than
70% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.37 vs. TEVA: 158.31 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 155.95  Med: 186.4 Max: 208.14
Current: 158.31
155.95
208.14
Days Sales Outstanding 116.23
TEVA's Days Sales Outstanding is ranked lower than
74% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.67 vs. TEVA: 116.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 120.04 Max: 153.21
Current: 116.23
95.91
153.21
Days Payable 65.33
TEVA's Days Payable is ranked lower than
56% of the 630 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.56 vs. TEVA: 65.33 )
Ranked among companies with meaningful Days Payable only.
TEVA' s Days Payable Range Over the Past 10 Years
Min: 65.33  Med: 78.39 Max: 84.39
Current: 65.33
65.33
84.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.26
TEVA's Dividend Yield % is ranked higher than
94% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. TEVA: 4.26 )
Ranked among companies with meaningful Dividend Yield % only.
TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.66  Med: 2.19 Max: 9.69
Current: 4.26
0.66
9.69
3-Year Dividend Growth Rate -14.70
TEVA's 3-Year Dividend Growth Rate is ranked lower than
74% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. TEVA: -14.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 23.6 Max: 80.9
Current: -14.7
-14.7
80.9
5-Year Yield-on-Cost % 3.81
TEVA's 5-Year Yield-on-Cost % is ranked higher than
94% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. TEVA: 3.81 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.59  Med: 1.96 Max: 8.67
Current: 3.81
0.59
8.67
3-Year Average Share Buyback Ratio -6.00
TEVA's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.00 vs. TEVA: -6.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -3.6 Max: 4.6
Current: -6
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.42
TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
96% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. TEVA: 0.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.4  Med: 2.69 Max: 9.51
Current: 0.42
0.4
9.51
Price-to-Median-PS-Value 0.36
TEVA's Price-to-Median-PS-Value is ranked higher than
96% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. TEVA: 0.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.18 Max: 2.24
Current: 0.36
0.35
2.24
Earnings Yield (Greenblatt) % -30.73
TEVA's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 868 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.18 vs. TEVA: -30.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33.6  Med: 4.8 Max: 8.8
Current: -30.73
-33.6
8.8
Forward Rate of Return (Yacktman) % 9.44
TEVA's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 411 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.51 vs. TEVA: 9.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2  Med: 22.9 Max: 45.5
Current: 9.44
-2
45.5

More Statistics

Revenue (TTM) (Mil) $22,385.00
EPS (TTM) $ -16.26
Beta0.81
Short Percentage of Float0.00%
52-Week Range $10.85 - 37.94
Shares Outstanding (Mil)1,016.88 (ADR)

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 19,393 18,994 19,154
EBIT (Mil $)
EBITDA (Mil $) 4,856 5,392 5,797
EPS ($) 2.89 3.43 3.78
EPS without NRI ($) 2.89 3.43 3.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-6.19%
Dividends per Share ($) 0.36 0.41 0.45

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}